Sandostatin Indications/Uses

Symptomatic control and reduction of growth hormone (GH) and IGF-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.
Relief of symptoms associated with functional gastro-entero-pancreatic (GEP) endocrine tumors: Carcinoid tumors with features of the carcinoid syndrome; VIPomas; Glucagonomas; Gastrinomas/Zollinger-Ellison syndrome, usually in conjunction with proton pump inhibitors, or H₂-antagonist therapy; Insulinomas, for pre-operative control of hypoglycemia and for maintenance therapy; GRFomas.
Sandostatin is not an anti-tumor therapy and is not curative in these patients.
Prevention of complications following pancreatic surgery.
Emergency management to stop bleeding and to protect from re-bleeding owing to gastro-esophageal varices in patients with cirrhosis. Sandostatin is to be used in association with specific treatment such as endoscopic sclerotherapy.